Purkiss Capital Advisors LLC Has $2.18 Million Stake in Johnson & Johnson $JNJ

Purkiss Capital Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 14,289 shares of the company’s stock after purchasing an additional 610 shares during the quarter. Johnson & Johnson comprises 1.2% of Purkiss Capital Advisors LLC’s holdings, making the stock its 15th largest position. Purkiss Capital Advisors LLC’s holdings in Johnson & Johnson were worth $2,183,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on JNJ shares. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Citigroup boosted their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Finally, Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $190.31 on Tuesday. The company has a fifty day moving average price of $182.54 and a two-hundred day moving average price of $166.65. The firm has a market capitalization of $458.50 billion, a PE ratio of 18.37, a P/E/G ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.